A Prospective Interventional Study on Early Screening for Lung Cancer Using Liquid Biopsy

Launched by THE FIRST AFFILIATED HOSPITAL OF GUANGZHOU MEDICAL UNIVERSITY · May 19, 2024

Keywords

ClinConnect Summary

This clinical trial, called the MERCURY pilot screening program, is part of the "Love Lung Project" and is designed to explore a new way to screen for lung cancer using a method called "liquid biopsy." This approach aims to detect lung cancer earlier, which can lead to better treatment outcomes and longer survival for patients. The researchers will compare the effectiveness of this liquid biopsy method to a traditional screening method called low-dose computer tomography (LDCT) to see which one works better in identifying lung cancer.

To participate in this study, individuals must be between the ages of 40 and 75 and should be willing to sign an informed consent form. However, certain people are not eligible, including those who are pregnant, have other active cancers, or have had recent lung scans within the past 1 to 3 years. Participants can expect to undergo a blood draw for the liquid biopsy and will be monitored throughout the study. This trial is not yet recruiting, but it aims to improve lung cancer screening and reduce unnecessary treatments for patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age greater than 40 years old and less than 75 years old, regardless of gender.
• • Sign the informed consent form.
• Exclusion Criteria:
• • Pregnant women;
• • Individuals currently diagnosed with any tumors other than lung cancer, or who have a history of cancer;
• • Those who have undergone LDCT/CT screening within the past 1-3 years;
• • Individuals currently suffering from a febrile illness, or who have had an acute inflammatory disease episode requiring internal medicine treatment within the last 14 days prior to blood draw;
• • Individuals who have taken corticosteroids orally or through intravenous injection within the 14 days prior to blood draw;
• • Organ transplant recipients or those who have previously received a non-autologous (allogeneic) bone marrow or stem cell transplant;
• • Individuals in poor health or not suitable for blood drawing;
• • Any other clinically significant disease or condition considered by the researchers to potentially affect adherence to the protocol, impact the patient's ability to provide informed consent, or render the patient unsuitable for participation in the clinical trial.